HanchorBio Inc.
1.12.2023 13:03:40 CET | ACCESS Newswire | Press release
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.
Title: An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio
Location: Palexpo, Geneva, Switzerland
Presentation Number: #10951
Date and Time: Thursday, 7 December 2023 at 12:00-13:00 CET
Highlights from the Preclinical Data-
Key findings from the preclinical studies of HCB101 targeting the SIRPa- CD47 pathway include:
- HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells;
- HCB101 consistently showed excellent efficacy against hematological and solid malignancies in 14 human tumor xenograft models;
- Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression inside the tumor compared to other competing molecules, suggesting a unique MOA underlying HCB101's superior efficacy;
- No adverse reaction was observed in cynomolgus monkey toxicology studies, indicating a good safety profile;
- HCB101 is currently being evaluated in a multi-regional, multi-center clinical study (NCT05892718) in the United States and Taiwan.
About HCB101
Discovered through structure-guided protein design which was further supplemented with relevant screening technologies, HCB101 is an engineered extracellular IgV domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of macrophages by blocking the "do not eat" signal between macrophages and the tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a much safer and more potent biologic than the anti-CD47 monoclonal antibodies and other SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. With IND clearance from the U.S. FDA and Taiwan FDA, HCB101 is currently being investigated in a multi-regional, multi-center, open-label, dose-finding clinical trial (NCT05892718) of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. Using HCB101 as the foundation, our multi-functional Fc-based designer biologics (FBDB™) platform pipeline includes other immune-modulating molecules targeting both adaptive and innate immunity to provide novel and efficacious treatments to patients suffering from difficult-to-treat cancers and other debilitating diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit HanchorBio or follow us on LinkedIn
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yuehua Cong
Chief Business Officer
yuehua_cong@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/811807/hanchorbio-to-present-at-the-esmo-immuno-oncology-2023-annual-congress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fidelity Investments Upgrades FINOS Membership to Platinum, Reinforcing Its Strategic Commitment to Open Source Collaboration in Financial Services11.2.2026 15:00:00 CET | Press release
Following its leadership in launching Fluxnova, Fidelity's appointment to the FINOS Governing Board underscores the growing recognition of the ROI of open source for all market participants NEW YORK CITY, NY / ACCESS Newswire / February 11, 2026 / The Fintech Open Source Foundation (FINOS), the foundation of open innovation in financial services, today announced that Fidelity Investments has upgraded its FINOS membership to Platinum, reflecting Fidelity's deepening strategic commitment to open source collaboration, industry interoperability, and the responsible adoption of emerging technologies such as AI across regulated financial services. The membership upgrade builds directly on Fidelity's role in the formation of Fluxnova, a FINOS-hosted open source orchestration platform created to address critical industry needs around workflow automation, vendor independence, and long-term infrastructure sustainability. Fidelity spearheaded the project's contribution into FINOS, helping establi
U.S. Marine Corps Selects GA-ASI for MUX TACAIR Collaborative Combat Aircraft Program10.2.2026 21:00:00 CET | Press release
GA-ASI's YFQ-42A Platform to Support Next-Generation Expeditionary Air Operations SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 10, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) was competitively selected by the U.S. Marine Corps (USMC) for evaluation in the Marine Air-Ground Task Force Uncrewed Expeditionary Tactical Aircraft (MUX TACAIR) Collaborative Combat Aircraft (CCA) program. The agreement integrates GA-ASI's expertise in autonomy and uncrewed aircraft systems with a government-provided mission package, usingthe YFQ-42A platform as a surrogate to evaluate integration with crewed fighters. The contract initiates integration of a Marine Corps mission kit into the YFQ-42A surrogate platform for assessment within the Marine Air Ground Task Force (MAGTF). The USMC contract includes the rapid development of autonomy for the government-supplied mission kit - a cost-effective, sensor-rich, software-defined suite capable of delivering kinetic and non-kinetic effects -
Changing Your Dog's Diet May Help the Planet More Than Changing Your Own, Study Finds10.2.2026 17:30:00 CET | Press release
LONDON, UK / ACCESS Newswire / February 10, 2026 / Diets high in meat, eggs, and dairy products incur significant environmental costs. But a new study has revealed that, in many cases, switching your dog to a more sustainable diet may have a bigger impact on the planet and farmed animals than changing your own diet. The research, published in the journal Animals by veterinary Professor Andrew Knight, found that the average dog consumes around 13 farmed land animals annually within its diet, compared with nine for the average person--a difference of roughly 40%. This gap exists largely because a greater proportion of a typical dog's dietary energy comes from animal-based ingredients--about 34%--compared to around 19% for people. These figures represent global averages and vary by country. In high-income nations such as the United States, consumption is higher across the board. There, an average person consumes 24 farmed land animals annually, compared with 20 for a dog--a smaller differ
Reco Raises $30M B Round for a Total of $85M to Meet Rapidly Growing Demand for AI SaaS Security Among Enterprises10.2.2026 16:30:00 CET | Press release
After growing ARR by 400% in 2025, Reco secures new backing months after its last funding to secure AI SaaS usage NEW YORK CITY, NEW YORK / ACCESS Newswire / February 10, 2026 / Reco, a leader in securing AI SaaS environments, today announced a $30 million Series B funding round led by Zeev Ventures, with participation from all existing investors including Insight Partners, boldstart ventures, while adding new corporate investors Workday Ventures, TIAA Ventures, S Ventures, and Quadrille Capital. The new funding comes less than 10 months after Reco's previous raise to meet the exponential demand to discover and secure AI SaaS at any modern enterprise. The round follows another year of exceptional growth for Reco. After growing 500% year-over-year in 2024, the company scaled an additional 400% in 2025 on a significantly larger base, driven by a sharp increase in enterprise AI adoption and the rapid rise of shadow AI, where 71% of knowledge workers now use AI tools without IT approval an
Logista Strator and Shekel Sign an Agreement to Bring Innovendi Elite to Spain - The Autonomous Sales Solution That Boosts Sales10.2.2026 14:05:00 CET | Press release
The goal is to put a technology in the hands of tobacconists and the Spanish retail sector to open new revenue channels. MADRID, ES / ACCESS Newswire / February 10, 2026 / Logista Strator, the technology platform specialized in retail management and part of Logista, has reached a strategic agreement with Shekel, developer of WeightAI™ technology and manufacturer of Innovendi Elite, for its distribution in Spain and Portugal. The companies will present the Innovendi Elite at the Hospitality Innovation Planet (HIP) trade fair in Madrid from February 16-18, 2026. Innovendi Elite is a next-generation smart fridge that redefines the future of vending experience: an advanced autonomous retail solution that combines patented weighing technology with artificial intelligence to deliver a completely frictionless shopping experience. Customers pay by card or app, open the cooler, select their products, and continue on their way without waiting. Its ability to operate in continuous mode and adapt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom